67,700 Shares in PROCEPT BioRobotics Corporation $PRCT Bought by Quantinno Capital Management LP

13 Aug 2026, 04:49 by Teresa Graham · The Cerbat Gem

Quantinno Capital Management LP purchased a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 67,700 shares of the company’s stock, valued at approximately $1,693,000. Quantinno Capital Management LP owned about 0.12% of PROCEPT BioRobotics at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its stake in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares in the last quarter. Center for Financial Planning Inc. purchased a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $40,000. Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics during the first quarter valued at about $42,000. US Bancorp DE lifted its position in shares of PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after purchasing an additional 1,079 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in PROCEPT BioRobotics during the fourth quarter worth about $68,000. 89.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PRCT has been the subject of a number of recent analyst reports. Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Evercore set a $23.00 target price on PROCEPT BioRobotics in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “hold” rating and set a $20.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, TD Cowen cut their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, PROCEPT BioRobotics currently has a consensus rating of “Hold” and a consensus price target of $28.00.

Get Our Latest Research Report on PROCEPT BioRobotics

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Larry L. Wood bought 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 1,000 shares of company stock valued at $28,480 over the last three months. Company insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Stock Down 7.2%

PRCT opened at $21.25 on Thursday. PROCEPT BioRobotics Corporation has a twelve month low of $16.67 and a twelve month high of $42.71. The company’s 50-day moving average price is $21.29 and its two-hundred day moving average price is $24.56. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -10.95 and a beta of 0.89. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.35) EPS. As a group, equities analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

Positive Sentiment: CEO Larry Wood purchased 23,900 shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may support investor confidence by signaling that management believes the stock is undervalued. SEC Form 4 filing
Neutral Sentiment: Several firms reiterated that investors who purchased PRCT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek lead-plaintiff status. These announcements are primarily procedural, but their frequency keeps legal uncertainty in focus. Securities class action deadline notice
Negative Sentiment: The complaints allege that PROCEPT and certain executives misrepresented demand for its robotic prostate-treatment systems, including repeated underperformance in handpiece sales and procedure activity. The allegations also point to excess customer inventory allegedly created by late-quarter bulk discounts, potentially making reported revenue and growth appear stronger than underlying demand. Hagens Berman class action announcement
Negative Sentiment: The litigation follows an approximately 18% share-price decline and could increase legal expenses, reputational risk, and scrutiny of PROCEPT’s sales strategy. The concerns are particularly significant because the company remains unprofitable and recently reported a quarterly loss that narrowly exceeded analyst expectations, despite revenue growth. Robbins Geller class action announcement

PROCEPT BioRobotics Profile

(Free Report)

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.